Dermatology News

Phase 3 results that supported the approval of roflumilast foam 0.3% for seborrheic dermatitis treatment showed that the drug was superior to vehicle for individuals aged 9 years and older in this indication, according to a study.

Ycanth has received a permanent J-code from the Centers for Medicare & Medicaid Services, Verrica Pharmaceuticals announced in a press release.

Atopic dermatitis in children may be associated with metabolic syndrome and nonalcoholic fatty liver disease, according to a study.

Pediatric patients with psoriasis experienced significant improvement with oral apremilast treatment, according to phase 3 trial results.

Researchers found that the efficacy of clascoterone cream 1% for the treatment of acne vulgaris increased over time up to 12 months and thus recommend persistent treatment regimens for optimal results, according to a study.

A phase 3 study subgroup analysis showed that patients with seborrheic dermatitis who cannot use topical steroids were more likely to achieve disease clearance with Zoryve topical foam vs. vehicle, Arcutis announced in a press release.

Dupixent for atopic dermatitis has received a label update from the FDA adding phase 3 efficacy and safety data, Regeneron and Sanofi announced in a press release.

Video education about topical corticosteroids alleviated caregivers’ concerns and improved outcomes for pediatric patients with eczematous dermatitis, according to a study published in Pediatric Dermatology.

According to analyses of new phase 3 data, patients with atopic dermatitis that were treated with Vtama cream 1% maintained long-term improvement even after stopping treatment, Dermavant announced in a press release.

Topical Zelsuvmi has been approved by the FDA for use in patients aged 1 year and older with molluscum contagiosum, Ligand Pharmaceuticals announced in a press release.